Immunoprecise Other Stockholder Equity vs Accounts Payable Analysis

IPA Stock

USD 0.56 0.01 1.75%

Immunoprecise Antibodies financial indicator trend analysis is infinitely more than just investigating Immunoprecise Antibodies recent accounting drivers to predict future trends. We encourage investors to analyze account correlations over time for multiple indicators to determine whether Immunoprecise Antibodies is a good investment. Please check the relationship between Immunoprecise Antibodies Other Stockholder Equity and its Accounts Payable accounts. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.

Other Stockholder Equity vs Accounts Payable

Other Stockholder Equity vs Accounts Payable Correlation Analysis

The overlapping area represents the amount of trend that can be explained by analyzing historical patterns of Immunoprecise Antibodies Other Stockholder Equity account and Accounts Payable. At this time, the significance of the direction appears to have significant contrarian relationship.

The correlation between Immunoprecise Antibodies' Other Stockholder Equity and Accounts Payable is -0.22. Overlapping area represents the amount of variation of Other Stockholder Equity that can explain the historical movement of Accounts Payable in the same time period over historical financial statements of Immunoprecise Antibodies, assuming nothing else is changed. The correlation between historical values of Immunoprecise Antibodies' Other Stockholder Equity and Accounts Payable is a relative statistical measure of the degree to which these accounts tend to move together. The correlation coefficient measures the extent to which Other Stockholder Equity of Immunoprecise Antibodies are associated (or correlated) with its Accounts Payable. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when Accounts Payable has no effect on the direction of Other Stockholder Equity i.e., Immunoprecise Antibodies' Other Stockholder Equity and Accounts Payable go up and down completely randomly.

Correlation Coefficient

-0.22

Relationship Direction	Negative
Relationship Strength	Insignificant

View All Relationships

Other Stockholder Equity

Accounts Payable

An accounting item on the balance sheet that represents Immunoprecise Antibodies obligation to pay off a short-term debt to its creditors. The accounts payable entry is usually reported under current liabilities. If accounts payable of Immunoprecise Antibodies are not paid within the agreed terms, the payables are considered to be in default, which may trigger a penalty or interest payment, or the revocation of additional credit from the supplier. Accounts payable may also be considered a source of cash, since they represent funds being borrowed from suppliers. Given these cash flow considerations, suppliers have a natural inclination to push for shorter payment terms, while creditors want to lengthen the payment terms. The amount a company owes to suppliers or vendors for products or services received but not yet paid for. It represents the company's short-term liabilities.

Most indicators from Immunoprecise Antibodies' fundamental ratios are interrelated and interconnected. However, analyzing fundamental ratios indicators one by one will only give a small insight into Immunoprecise Antibodies current financial condition. On the other hand, looking into the entire matrix of fundamental ratios indicators, and analyzing their relationships over time can provide a more complete picture of the company financial strength now and in the future. Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.The current year's Selling General Administrative is expected to grow to about 16.4 M, whereas Tax Provision is projected to grow to (1.4 M).

	2021	2022	2023	2024 (projected)
Gross Profit	11.0M	11.6M	12.1M	12.7M
Total Revenue	19.4M	20.7M	24.5M	25.7M

Gross Profit Total Revenue

Immunoprecise Antibodies fundamental ratios Correlations

	Total Assets	Other Current Liab	Total Current Liabilities	Total Stockholder Equity	Property Plant And Equipment Net	Net Debt	Retained Earnings	Accounts Payable	Cash	Non Current Assets Total	Cash And Short Term Investments	Net Receivables	Common Stock Shares Outstanding	Short Term Investments	Other Current Assets	Other Stockholder Equity	Total Liab	Total Current Assets	Non Current Liabilities Total	Non Currrent Assets Other	Short Long Term Debt Total	Property Plant And Equipment Gross	Short Term Debt	Inventory	Current Deferred Revenue	Intangible Assets
Total Assets		0.43	0.86	0.98	0.68	-0.41	-0.73	0.95	0.69	0.93	0.69	0.9	0.92	-0.26	0.97	-0.21	0.86	0.78	0.79	-0.31	0.59	0.76	0.57	0.85	0.81	0.9
Other Current Liab	0.43		0.74	0.38	0.12	-0.18	-0.1	0.45	0.3	0.39	0.29	0.54	0.46	-0.26	0.29	-0.51	0.48	0.37	0.29	-0.07	0.19	0.11	0.78	0.53	0.59	0.3
Total Current Liabilities	0.86	0.74		0.78	0.67	-0.19	-0.67	0.91	0.49	0.85	0.48	0.92	0.91	-0.33	0.75	-0.37	0.9	0.59	0.77	-0.29	0.66	0.7	0.83	0.9	0.94	0.76
Total Stockholder Equity	0.98	0.38	0.78		0.54	-0.57	-0.62	0.88	0.8	0.86	0.79	0.81	0.83	-0.23	0.99	-0.2	0.74	0.87	0.65	-0.31	0.44	0.64	0.52	0.76	0.73	0.86
Property Plant And Equipment Net	0.68	0.12	0.67	0.54		0.27	-0.96	0.81	0.1	0.8	0.1	0.79	0.87	-0.16	0.59	0.0	0.9	0.2	0.95	-0.28	0.95	0.98	0.31	0.79	0.73	0.67
Net Debt	-0.41	-0.18	-0.19	-0.57	0.27		-0.19	-0.21	-0.93	-0.07	-0.93	-0.17	-0.08	0.07	-0.52	0.17	0.06	-0.87	0.2	0.11	0.33	0.2	-0.17	-0.06	-0.14	-0.16
Retained Earnings	-0.73	-0.1	-0.67	-0.62	-0.96	-0.19		-0.83	-0.17	-0.85	-0.16	-0.77	-0.87	0.26	-0.67	-0.18	-0.89	-0.27	-0.94	0.44	-0.85	-0.98	-0.33	-0.81	-0.69	-0.75
Accounts Payable	0.95	0.45	0.91	0.88	0.81	-0.21	-0.83		0.54	0.94	0.53	0.92	0.96	-0.31	0.88	-0.22	0.95	0.63	0.9	-0.25	0.76	0.86	0.56	0.87	0.86	0.86
Cash	0.69	0.3	0.49	0.8	0.1	-0.93	-0.17	0.54		0.38	1.0	0.5	0.43	-0.17	0.76	-0.21	0.3	0.98	0.17	-0.21	0.03	0.16	0.33	0.38	0.46	0.41
Non Current Assets Total	0.93	0.39	0.85	0.86	0.8	-0.07	-0.85	0.94	0.38		0.38	0.88	0.95	-0.27	0.87	-0.15	0.94	0.5	0.91	-0.28	0.73	0.89	0.55	0.88	0.79	0.95
Cash And Short Term Investments	0.69	0.29	0.48	0.79	0.1	-0.93	-0.16	0.53	1.0	0.38		0.49	0.42	-0.13	0.75	-0.21	0.29	0.98	0.16	-0.22	0.02	0.15	0.32	0.37	0.44	0.4
Net Receivables	0.9	0.54	0.92	0.81	0.79	-0.17	-0.77	0.92	0.5	0.88	0.49		0.97	-0.33	0.83	-0.33	0.93	0.61	0.86	-0.23	0.78	0.81	0.64	0.87	0.96	0.77
Common Stock Shares Outstanding	0.92	0.46	0.91	0.83	0.87	-0.08	-0.87	0.96	0.43	0.95	0.42	0.97		-0.33	0.84	-0.24	0.98	0.55	0.93	-0.27	0.84	0.9	0.62	0.94	0.91	0.85
Short Term Investments	-0.26	-0.26	-0.33	-0.23	-0.16	0.07	0.26	-0.31	-0.17	-0.27	-0.13	-0.33	-0.33		-0.25	0.02	-0.3	-0.18	-0.26	-0.1	-0.27	-0.19	-0.29	-0.29	-0.36	-0.26
Other Current Assets	0.97	0.29	0.75	0.99	0.59	-0.52	-0.67	0.88	0.76	0.87	0.75	0.83	0.84	-0.25		-0.14	0.75	0.83	0.69	-0.32	0.48	0.69	0.46	0.74	0.73	0.87
Other Stockholder Equity	-0.21	-0.51	-0.37	-0.2	0.0	0.17	-0.18	-0.22	-0.21	-0.15	-0.21	-0.33	-0.24	0.02	-0.14		-0.21	-0.24	-0.09	-0.63	-0.24	0.01	-0.43	-0.22	-0.41	-0.16
Total Liab	0.86	0.48	0.9	0.74	0.9	0.06	-0.89	0.95	0.3	0.94	0.29	0.93	0.98	-0.3	0.75	-0.21		0.42	0.97	-0.25	0.87	0.92	0.57	0.91	0.88	0.82
Total Current Assets	0.78	0.37	0.59	0.87	0.2	-0.87	-0.27	0.63	0.98	0.5	0.98	0.61	0.55	-0.18	0.83	-0.24	0.42		0.29	-0.24	0.13	0.27	0.43	0.49	0.56	0.53
Non Current Liabilities Total	0.79	0.29	0.77	0.65	0.95	0.2	-0.94	0.9	0.17	0.91	0.16	0.86	0.93	-0.26	0.69	-0.09	0.97	0.29		-0.2	0.91	0.97	0.38	0.84	0.77	0.78
Non Currrent Assets Other	-0.31	-0.07	-0.29	-0.31	-0.28	0.11	0.44	-0.25	-0.21	-0.28	-0.22	-0.23	-0.27	-0.1	-0.32	-0.63	-0.25	-0.24	-0.2		-0.02	-0.3	-0.3	-0.37	-0.21	-0.23
Short Long Term Debt Total	0.59	0.19	0.66	0.44	0.95	0.33	-0.85	0.76	0.03	0.73	0.02	0.78	0.84	-0.27	0.48	-0.24	0.87	0.13	0.91	-0.02		0.91	0.35	0.75	0.76	0.6
Property Plant And Equipment Gross	0.76	0.11	0.7	0.64	0.98	0.2	-0.98	0.86	0.16	0.89	0.15	0.81	0.9	-0.19	0.69	0.01	0.92	0.27	0.97	-0.3	0.91		0.34	0.82	0.73	0.79
Short Term Debt	0.57	0.78	0.83	0.52	0.31	-0.17	-0.33	0.56	0.33	0.55	0.32	0.64	0.62	-0.29	0.46	-0.43	0.57	0.43	0.38	-0.3	0.35	0.34		0.71	0.77	0.56
Inventory	0.85	0.53	0.9	0.76	0.79	-0.06	-0.81	0.87	0.38	0.88	0.37	0.87	0.94	-0.29	0.74	-0.22	0.91	0.49	0.84	-0.37	0.75	0.82	0.71		0.84	0.8
Current Deferred Revenue	0.81	0.59	0.94	0.73	0.73	-0.14	-0.69	0.86	0.46	0.79	0.44	0.96	0.91	-0.36	0.73	-0.41	0.88	0.56	0.77	-0.21	0.76	0.73	0.77	0.84		0.71
Intangible Assets	0.9	0.3	0.76	0.86	0.67	-0.16	-0.75	0.86	0.41	0.95	0.4	0.77	0.85	-0.26	0.87	-0.16	0.82	0.53	0.78	-0.23	0.6	0.79	0.56	0.8	0.71

Click cells to compare fundamentals

Immunoprecise Antibodies Account Relationship Matchups

Immunoprecise Antibodies fundamental ratios Accounts

	2019	2020	2021	2022	2023	2024 (projected)
Total Assets	27.3M	67.0M	93.5M	77.8M	60.0M	63.0M
Other Current Liab	1.8M	964K	1.3M	441K	837K	575.3K
Total Current Liabilities	7.9M	6.1M	9.3M	5.9M	8.1M	8.5M
Total Stockholder Equity	15.1M	56.9M	75.3M	57.8M	33.9M	35.6M
Property Plant And Equipment Net	3.2M	4.1M	3.7M	10.7M	17.2M	18.0M
Net Debt	1.9M	(38.3M)	(27.4M)	(1.0M)	10.2M	10.7M
Retained Earnings	(22.5M)	(29.8M)	(46.5M)	(73.1M)	(100.3M)	(95.3M)
Accounts Payable	1.8M	3.0M	4.8M	3.4M	4.4M	4.6M
Cash	2.6M	41.8M	30.0M	8.3M	3.5M	4.0M
Non Current Assets Total	19.6M	18.1M	56.0M	61.0M	48.5M	50.9M
Cash And Short Term Investments	2.6M	41.8M	30.0M	8.3M	3.5M	4.1M
Net Receivables	3.7M	4.1M	3.4M	4.4M	4.5M	4.7M
Common Stock Shares Outstanding	13.6M	16.5M	19.7M	24.9M	25.6M	26.9M
Liabilities And Stockholders Equity	27.3M	67.0M	93.5M	77.8M	60.0M	63.0M
Other Current Assets	614.0K	2.3M	2.8M	2.6M	1.4M	1.5M
Other Stockholder Equity	3.5M	6.6M	7.3M	10.8M	12.4M	9.2M
Total Liab	12.2M	10.0M	18.2M	20.0M	26.1M	27.4M
Total Current Assets	7.7M	48.9M	37.5M	16.8M	11.5M	6.0M
Non Current Liabilities Total	4.2M	4.0M	8.9M	14.1M	17.9M	18.8M
Non Currrent Assets Other	85.1K	79K	82K	86K	77.4K	73.5K
Short Long Term Debt Total	4.5M	3.5M	2.5M	7.3M	13.7M	14.4M
Property Plant And Equipment Gross	3.1M	4.1M	9.4M	17.1M	21.5M	22.6M
Accumulated Other Comprehensive Income	(300.2K)	(687K)	(2.5M)	2.6M	2.0M	2.1M
Short Term Debt	2.9M	986K	2.2M	1.1M	1.6M	1.1M
Inventory	818.6K	1.2M	1.6M	2.1M	2.1M	2.2M
Current Deferred Revenue	1.5M	1.1M	1.0M	977K	1.4M	1.4M
Intangible Assets	8.3M	6.1M	32.4M	30.9M	23.6M	15.6M
Common Stock	34.1M	80.1M	114.6M	117.5M	119.8M	125.8M
Net Tangible Assets	(1.0M)	43.1M	23.2M	7.7M	8.9M	12.5M
Net Invested Capital	17.7M	58.5M	76.6M	57.8M	33.9M	39.2M
Net Working Capital	(230.3K)	42.8M	28.2M	10.9M	3.4M	3.2M
Property Plant Equipment	3.1M	4.0M	3.3M	10.4M	12.0M	12.5M
Other Liab	2.6M	1.5M	8.6M	7.9M	9.1M	5.1M
Other Assets	287.6K	163K	476K	437K	393.3K	373.6K
Good Will	7.9M	7.8M	19.7M	19.2M	7.7M	11.8M
Capital Lease Obligations	1.9M	1.9M	1.2M	7.3M	13.7M	14.4M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

AVAV	AeroVironment
ELVN	Enliven Therapeutics
NFLX	Netflix

When determining whether Immunoprecise Antibodies offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Immunoprecise Antibodies' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Immunoprecise Antibodies Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Immunoprecise Antibodies Stock:

How To Invest In Immunoprecise

Details

Is Immunoprecise Stock a good investment?

Details

What is Immunoprecise Antibodies' Net Worth?

Details

Largest Biotechnology Companies

View

Largest Pharmaceuticals, Biotechnology & Life Sciences Companies

View

Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Immunoprecise Antibodies. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in american community survey.

For information on how to trade Immunoprecise Stock refer to our How to Trade Immunoprecise Stock guide.

You can also try the Headlines Timeline module to stay connected to all market stories and filter out noise. Drill down to analyze hype elasticity.

Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Immunoprecise Antibodies. If investors know Immunoprecise will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Immunoprecise Antibodies listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.

Earnings Share

(0.76)

Revenue Per Share

0.921

Quarterly Revenue Growth

(0.07)

Return On Assets

(0.13)

Return On Equity

(0.64)

The market value of Immunoprecise Antibodies is measured differently than its book value, which is the value of Immunoprecise that is recorded on the company's balance sheet. Investors also form their own opinion of Immunoprecise Antibodies' value that differs from its market value or its book value, called intrinsic value, which is Immunoprecise Antibodies' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Immunoprecise Antibodies' market value can be influenced by many factors that don't directly affect Immunoprecise Antibodies' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.

Please note, there is a significant difference between Immunoprecise Antibodies' value and its price as these two are different measures arrived at by different means. Investors typically determine if Immunoprecise Antibodies is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Immunoprecise Antibodies' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2024 Macroaxis LLC

Immunoprecise Other Stockholder Equity vs Accounts Payable Analysis

Other Stockholder Equity vs Accounts Payable

Other Stockholder Equity vs Accounts Payable Correlation Analysis

Correlation Coefficient

Other Stockholder Equity

Accounts Payable

Immunoprecise Antibodies fundamental ratios Correlations

Immunoprecise Antibodies Account Relationship Matchups

High Positive Relationship

High Negative Relationship

Immunoprecise Antibodies fundamental ratios Accounts

Also Currently Popular

COMMON DESTINATIONS

MAIN CATEGORIES

COMPANY

Cash And Short Term Investments	+ 1.0	Cash
Other Current Assets	+ 0.99	Total Stockholder Equity
Total Stockholder Equity	+ 0.98	Total Assets
Property Plant And Equipment Gross	+ 0.98	Property Plant And Equipment Net
Total Current Assets	+ 0.98	Cash
Total Current Assets	+ 0.98	Cash And Short Term Investments

Property Plant And Equipment Gross	- 0.98	Retained Earnings
Retained Earnings	- 0.96	Property Plant And Equipment Net
Non Current Liabilities Total	- 0.94	Retained Earnings
Cash And Short Term Investments	- 0.93	Net Debt
Cash	- 0.93	Net Debt
Total Liab	- 0.89	Retained Earnings